Bauman Megan M J, Bouchal Samantha M, Kerezoudis Panagiotis, Cloft Harry, Brinjikji Waleed, Peris Celda Maria, Link Michael J, Parney Ian F
Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States.
J Neurol Surg B Skull Base. 2022 Nov 16;84(6):598-608. doi: 10.1055/a-1946-4604. eCollection 2023 Dec.
Hemangioblastomas pose an inherent surgical risk due to the potential for high intraoperative blood loss, especially in larger tumors. One approach to minimize this risk is to use preoperative embolization. Herein, we present our institutional experience treating large and giant cerebellar hemangioblastomas. We performed a retrospective chart review of 19 patients with cerebellar hemangioblastomas that had a maximal diameter of >3 cm. We performed a literature review and included individual patient-level data that met our >3 cm diameter cerebellar hemangioblastoma inclusion criteria. Our cohort consisted of 19 patients that received a total of 20 resections for their cerebellar hemangioblastomas. Preoperative embolization was utilized in eight cases (38.1%). One patient experienced transient neurological complications after embolization (12.5%). Tumors of patients in the embolization group had larger median total, solid, and cystic volumes and were more likely to involve the cerebellopontine angle than those in the non-embolized group. Compared with non-embolized patients, embolized patients had less decrease in their hemoglobin, lower volumes of estimated blood loss, reduced rates of postoperative complications and permanent deficits, and greater instances of neurological improvement. The larger cohort (obtained from the combining our cohort with patients identified during a literature review) consisted of 99 patients with 39 receiving preoperative embolization. It is important to examine individual patient characteristics when determining eligibility for preoperative embolization. However, improvements in endovascular techniques have made preoperative embolization a safe and effective procedure with minimal risks that can be performed in many patients.
由于术中大量失血的可能性,尤其是较大的肿瘤,血管母细胞瘤存在固有的手术风险。将这种风险降至最低的一种方法是采用术前栓塞。在此,我们介绍我们机构治疗大型和巨大型小脑血管母细胞瘤的经验。
我们对19例最大直径>3 cm的小脑血管母细胞瘤患者进行了回顾性病历审查。我们进行了文献综述,并纳入了符合我们直径>3 cm小脑血管母细胞瘤纳入标准的个体患者水平数据。
我们的队列包括19例患者,他们因小脑血管母细胞瘤共接受了20次切除术。8例(38.1%)采用了术前栓塞。1例患者栓塞后出现短暂性神经并发症(12.5%)。栓塞组患者的肿瘤总体积、实性体积和囊性体积中位数更大,比未栓塞组更易累及小脑脑桥角。与未栓塞患者相比,栓塞患者的血红蛋白下降较少,估计失血量较少,术后并发症和永久性神经功能缺损发生率较低,神经功能改善的情况更多。更大的队列(通过将我们的队列与文献综述中确定的患者相结合获得)包括99例患者,其中39例接受了术前栓塞。
在确定术前栓塞的适用性时,检查个体患者特征很重要。然而,血管内技术的进步使术前栓塞成为一种安全有效的手术,风险极小,许多患者都可以进行。